Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1628
This examiner grants 0% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18415255 | USES OF HNF4 ALPHA AGONISTS | Non-Final OA | Sanford Burnham Prebys Medical Discovery Institute |
| 18392229 | USE OF L-ERGOTHIONEINE FOR ALLEVIATING AND PREVENTING AGE-RELATED VISUAL DEGENERATION | Non-Final OA | NANJING NUTRABUILDING BIO-TECH CO., LTD. |
| 18572651 | COMPOSITIONS COMPRISING AN AGONIST OF 5-HYDROXYTRYPTAMINE (5-HT) RECEPTOR SUBTYPE 3 | Non-Final OA | LDN Pharma Limited |
| 18510944 | LFA-1 ANTAGONISTS FOR TREATING INFLAMMATORY BOWEL DIESEASE | Non-Final OA | VivaVision Biotech, Inc |
| 18508992 | TRAZODONE ORAL SOLUTION | Non-Final OA | OWP Pharmaceuticals, Inc. |
| 18387913 | PPARG INVERSE AGONISTS AND USES THEREOF | Non-Final OA | Flare Therapeutics Inc. |
| 18041682 | POLYMORPHS OF 5-BROMO-6-CHLORO-3-INDOXYL CAPRYLATE | Non-Final OA | Biosynth AG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy